Andrew Bragagnini, PA
Physician Assistant · Hammond, LANPI 1629672308
Payments from drug & device makers
Across 562 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Calliditas Therapeutics US Inc.$992
- Otsuka America Pharmaceutical, Inc.$920
- Amgen$819
- Bayer$720
- OPKO Pharmaceuticals, LLC$711
- AstraZeneca$664
- plus $5K from 29 others
What the payments were for
- Food & beverage$9,633100%
- Education$330%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Calliditas Therapeutics US Inc. | 50 | $992 |
| Otsuka America Pharmaceutical, Inc. | 51 | $920 |
| Amgen(2 entities) | 57 | $819 |
| Bayer | 54 | $720 |
| OPKO Pharmaceuticals, LLC | 49 | $711 |
| AstraZeneca(2 entities) | 38 | $664 |
| Fresenius USA Marketing, Inc. | 39 | $620 |
| Vifor Pharma, Inc. | 36 | $619 |
| Aurinia Pharma U.S., Inc. | 30 | $542 |
| GSK | 36 | $527 |
| Akebia Therapeutics Inc | 18 | $331 |
| Shield Therapeutics Inc | 18 | $305 |
| Daiichi Sankyo Inc. | 12 | $239 |
| Mallinckrodt Hospital Products Inc. | 11 | $215 |
| Boehringer Ingelheim | 12 | $212 |
| Novo Nordisk | 4 | $155 |
| ANI Pharmaceuticals, Inc. | 6 | $127 |
| Travere Therapeutics, Inc. | 8 | $123 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $118 |
| Sanofi | 4 | $112 |
| Novartis | 4 | $108 |
| Scpharmaceuticals Inc. | 5 | $92 |
| Bard Peripheral Vascular, Inc. | 1 | $64 |
| Lilly USA, LLC | 3 | $50 |
| Pharmacosmos Therapeutics Inc. | 2 | $42 |
| Cormedix Inc. | 2 | $41 |
| Ardelyx, Inc. | 2 | $40 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| Renalytix AI, Inc. | 1 | $23 |
| Mannkind Corporation | 1 | $19 |
| AbbVie | 1 | $18 |
| Merck | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,666 in reported general payments places this provider in the 95th percentile of 1,246 physician assistant providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 69 | $61,447 |
| RayaldeeCalcifediol | 38 | $53,321 |
| JardianceEmpagliflozin | 25 | $23,055 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $10,773 |
| EntrestoSacubitril/Valsartan | 16 | $10,509 |
| Cinacalcet Hcl | 95 | $6,454 |
| Megestrol Acetate | 14 | $3,338 |
| Calcitriol | 453 | $3,091 |
| Nifedipine ErNifedipine | 135 | $1,182 |
| Telmisartan | 36 | $1,094 |
| Allopurinol | 209 | $971 |
| Febuxostat | 29 | $958 |
| Hydralazine Hcl | 80 | $797 |
| Olmesartan Medoxomil | 109 | $584 |
| Potassium Chloride | 57 | $542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $720 | $61,44769 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $711 | $53,32138 claims |
| Boehringer IngelheimJardiance | $212 | $23,05525 claims |
| AstraZenecaLokelma | $664 | $10,77314 claims |
| NovartisEntresto | $108 | $10,50916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 physician assistant providers in Louisiana.
Other physician assistant in Hammond
- Shelly EsnardBaton Rouge$141K
- Jefferson OberleNew Orleans$66K
- Jennifer ScheuermannNew Orleans$56K
- Claire DarreJefferson$50K
- Elizabeth ClementNew Orleans$35K
- Mary Negrotto GuntherSlidell$29K
- Kristen HebertZachary$27K
- David GsellNew Orleans$26K
- Nakia BrooksNew Orleans$25K
- Savannah SanchezBaton Rouge$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.